We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 304.00
Bid: 301.00
Ask: 304.00
Change: 14.00 (4.83%)
Spread: 3.00 (0.997%)
Open: 310.00
High: 314.00
Low: 304.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chi-Med to Attend Upcoming Investor Conferences

11 May 2020 07:00

RNS Number : 3486M
Hutchison China Meditech Limited
11 May 2020
 

Press Release

Chi-Med to Attend Upcoming Investor Conferences

London: Friday, May 11, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT).

 

The discussion will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

 

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

 

· Citi Virtual Pan-Asia Regional Investor Conference from Tuesday to Thursday, May 19 to 21, 2020;

 

· Jefferies Virtual Global Healthcare Conference from Tuesday to Thursday, June 2 to 4, 2020; and

 

· Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Thursday, June 9 to 11, 2020.

 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

CONTACTS

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMZGGKRRZGGZG
Date   Source Headline
16th Jul 202110:50 amRNSHolding(s) in Company
16th Jul 20217:00 amRNSSurufatinib MAA Submitted and Validated by the EMA
14th Jul 20219:35 amRNSHolding(s) in Company
13th Jul 20217:00 amRNSFirst Commercial Sale of ORPATHYS® in China
12th Jul 20212:35 pmRNSFull Exercise of the Over-allotment Option
6th Jul 20219:30 amRNSHUTCHMED Initiates Phase I Trials of HMPL-295
2nd Jul 202111:15 amRNSHolding(s) in Company
2nd Jul 20219:30 amRNSNotice of Results
1st Jul 202111:00 amRNSUS FDA Accepts NDA Filing for Surufatinib
30th Jun 202110:02 amRNSHoldings in Company
30th Jun 202110:01 amRNSTotal Voting Rights
30th Jun 202110:00 amRNSClosing of Global Offering and Hong Kong Listing
29th Jun 20217:00 amRNSBlocklisting Six Monthly Return
23rd Jun 20213:21 pmRNSHUTCHMED Announces Pricing of Global Offering
22nd Jun 20216:22 pmRNSSavolitinib approved in China for lung cancer
18th Jun 20214:05 pmRNSHUTCHMED Announces NMPA Approval of Surufatinib
18th Jun 20217:01 amRNSHUTCHMED Launches Hong Kong IPO
18th Jun 20217:00 amRNSDisclosure Update
20th May 20217:00 amRNSClinical Data to be Presented at ASCO21
17th May 20217:00 amRNSHUTCHMED to Host Company Update
7th May 202112:00 pmRNSHUTCHMED to Attend Upcoming Investor Conferences
4th May 20218:00 amRNSChange of Company Name
4th May 20217:00 amRNSSurufatinib FDA Rolling NDA Submission Completed
30th Apr 20214:41 pmRNSSecond Price Monitoring Extn
30th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSPhase II Registration Study of HMPL-689 Initiated
28th Apr 20212:20 pmRNSResult of AGM
23rd Apr 20217:00 amRNSVesting of awards under Long Term Incentive Plan
14th Apr 202110:30 amRNSNotification of Dilution of Voting Rights
8th Apr 20218:30 amRNS$100m Investment by Baring Private Equity Asia
31st Mar 20217:00 amRNSTotal Voting Rights
29th Mar 20219:30 amRNSGrant of LTIP Awards and Share Options
29th Mar 20217:00 amRNSInitiates International Phase I Trials of HMPL-306
26th Mar 20217:00 amRNSAnnual Financial Report
24th Mar 20211:30 pmRNSAgreement to Divest Non-Core OTC Joint Venture
24th Mar 20217:00 amRNSPhase Ib/II Trial of Surufatinib with Tislelizumab
10th Mar 20217:00 amRNSVesting of awards under Long Term Incentive Plan
4th Mar 20213:15 pmRNSPublication of Form 20-F
4th Mar 202112:00 pmRNSFinal Results, Business Update and Name Change
3rd Feb 20217:00 amRNSNotice of Results
14th Jan 202110:00 amRNSSavolitinib Data to be Presented at Virtual WCLC
11th Jan 20217:00 amRNSChi-Med & Inmagene Announce Strategic Partnership
31st Dec 20207:00 amRNSBlocklisting Six Monthly Return
31st Dec 20207:00 amRNSTotal Voting Rights
30th Dec 202012:00 pmRNSNMPA approval of Surufatinib in China for ep-NET
29th Dec 20207:45 amRNSUS NDA Rolling Submission of Surufatinib Initiated
22nd Dec 20207:00 amRNSChi-Med to Present at JPM
15th Dec 20209:45 amRNSGrant of Share Options under Share Option Scheme
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSNotification of Dilution of Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.